Assembly Biosciences, Inc. (ASMB), a biotechnology company, Thursday announced encouraging interim data from Phase 1b study of ...

编者按在慢性乙型肝炎（CHB）的治疗领域，追求功能性治愈已逐步成为共识，但这并不意味着放弃对疾病的根治追求。2024年12月20~22日，在首届“井冈星火”消化肝病高峰论坛上，北京大学医学部庄辉院士在会上作了关于“功能性治愈是CHB治疗的主要终点”的 ...

Vaccines have saved 174 million lives over the past 50 years, according to “The most comprehensive modeling analysis of historical vaccine impact,” as reported in the highly respected medical journal ...

HYDERABAD: With approximately a 150% increase in Hepatitis B cases and a 100% increase in Hepatitis C cases, Telangana has ...

In September 2024, the Food and Drug Administration (FDA) approved a label update for Heplisav-B (hepatitis B vaccine ...

Vaccination has long been one of the most effective tools to prevent serious illnesses. Many countries have achieved high ...

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the ...

Patients with liver cirrhosis achieved higher levels of seroprotection against HBV and improved immunogenicity via alternative vaccination strategies.

The global cirrhosis management market is projected to grow from US$ 725 million in 2023 to US$ 1,052.3 million by 2033, with ...

About Bluejay Therapeutics Bluejay Therapeutics is a clinical-stage biopharmaceutical company focused on the development of potentially life-changing treatments for viral hepatitis and liver diseases.

Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding. Gilead is buying the additional Assembly Bio stock, ...